By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Development and advancement of a product pipeline for the treatment of severe allergic reactions44.55M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States29.6M66.46%
Ex-United States14.94M33.54%